Skip to content
HowShorted

PTC Therapeutics, Inc. short interest in 2018

In 2018, PTC Therapeutics, Inc.'s disclosed short interest ran from 15.77% of shares outstanding on 12 Jan 2018 to 7.64% on 31 Dec 2018, a change of -8.13 percentage points. The year's high was 16.18% on 31 Jan 2018 and its low 6.95% on 15 Aug 2018, averaging 9.87% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.32 days on 15 Feb 2018. Full history: PTC Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for PTC Therapeutics, Inc. in 2018

2018 in figures

Start of year
15.77% (12 Jan 2018)
End of year
7.64% (31 Dec 2018)
Change
-8.13 pp
High
16.18% (31 Jan 2018)
Low
6.95% (15 Aug 2018)
Average
9.87%
Highest days to cover
9.32 (15 Feb 2018)
SEC filings marked
9

Every report in 2018

PTC Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201815.77%5.00results (8-K)
31 Jan 201816.18%5.39
15 Feb 201815.76%9.32
28 Feb 201814.69%7.61
15 Mar 201814.76%6.6810-K filed, results (8-K)
29 Mar 201813.21%3.95
13 Apr 201810.19%4.88
30 Apr 20189.30%5.60
15 May 20188.32%4.0110-Q filed, results (8-K)
31 May 20188.62%4.97
15 Jun 20189.06%4.67
29 Jun 20187.57%1.00
13 Jul 20187.72%4.97
31 Jul 20187.40%3.19
15 Aug 20186.95%4.2610-Q filed, results (8-K)
31 Aug 20187.31%4.02
14 Sep 20187.51%3.21
28 Sep 20187.95%3.79
15 Oct 20188.69%3.88
31 Oct 20188.08%6.32
15 Nov 20188.22%4.7410-Q filed, results (8-K)
30 Nov 20188.43%6.89
14 Dec 20187.66%6.24
31 Dec 20187.64%5.26

See also: PTC Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.